CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...6970717273747576777879...39323933»
  • ||||||||||  RP3 / Replimune
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (clinicaltrials.gov) -  Aug 5, 2024   
    P1,  N=123, Active, not recruiting, 
    N=50 --> 0 | Trial completion date: Dec 2036 --> Aug 2024 | Suspended --> Withdrawn | Trial primary completion date: Dec 2034 --> Aug 2024 Trial completion date: Apr 2024 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Nov 2026
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (clinicaltrials.gov) -  Aug 4, 2024   
    P1/2,  N=30, Active, not recruiting, 
    Trial completion date: Dec 2026 --> Aug 2025 | Trial primary completion date: Dec 2026 --> Apr 2024 Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial (Exhibit Hall) -  Aug 4, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2700;    
    The study is open for enrollment in centres across the USA, Belgium, Italy, Spain, France, Japan and Korea. Adult treatment-nai?ve NSCLC patients with BM and no EGFR/ALK alterations were randomized at 1:1 to receive camrelizumab (200mg) or placebo, plus platinum-doublet chemotherapy on day 1 of each 3-week cycle for 4-6 cycles, followed by maintenance camrelizumab or placebo
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer (Exhibit Hall) -  Aug 4, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2696;    
    P3
    Other secondary endpoints include investigator-assessed PFS, investigator and BICR-assessed objective response rate, disease control rate, duration of response, time to progression (all per RECIST 1.1), incidence of treatment-emergent and treatment-related adverse events, serum concentrations of tarlatamab, and incidence of anti-tarlatamab antibody formation. This trial is actively recruiting patients.
  • ||||||||||  nibrozetone (RRx-001) / EpicentRx
    Preclinical, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker:  CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro-immunogenic response, reduced toxicity, and tumor free survival in mice bearing glioblastoma. (Pubmed Central) -  Aug 4, 2024   
    To overcome these issues, in this study, we have developed a multifunctional Immunosome where ?CD40 is conjugated on the surface and RRX-001, a small molecule immunomodulator was encapsulated inside it...In addition, Immunosomes treated long-term surviving mice showed tumor specific immune memory response which prevented tumor growth upon rechallenge. Our results suggested that this novel formulation can be further explored in clinics to improve in vivo anti-tumor efficacy of ?CD40 with long-lasting tumor specific immunity while reducing the associated toxicities.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Renal cell carcinoma. (Pubmed Central) -  Aug 4, 2024   
    Developments in adjuvant therapies are discussed, including use of pembrolizumab-the first therapy to achieve overall survival benefit in the adjuvant setting...Management of non-clear cell renal cell carcinoma subtypes is also reviewed. Future directions of research, including a discussion of ongoing clinical trials and the need for reliable biomarkers to guide treatment in kidney cancer, are also highlighted.
  • ||||||||||  Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
    Review, Journal:  The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine? (Pubmed Central) -  Aug 4, 2024   
    Our findings may pave further in detailed mechanistic study on these complexes as potential chemotherapeutic agents in different types of human cancers. However, despite their therapeutic efficacy, Bexxar
  • ||||||||||  Review, Journal, HEOR, CAR T-Cell Therapy:  Economic Evaluations of CAR-T Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review. (Pubmed Central) -  Aug 4, 2024   
    CAR-T therapies were more expensive and generated more QALYs than comparators, but their cost-effectiveness was uncertain and dependent on patient population, cancer type, and model assumptions. This highlights the need for more nuanced economic evaluations and continued research to better understand the value of CAR-T therapies in diverse patient populations.